Literature DB >> 31404017

Defining Pancreatitis as a Risk Factor for Pancreatic Cancer: The Role, Incidence, and Timeline of Development.

Aslam Syed1,2, Olivia Babich1, Payal Thakkar3, Arjun Patel1, Heitham Abdul-Baki1, Katie Farah1, Suzanne Morrissey1, Marcia Mitre1, Manish Dhawan1, Gursimran Kochhar1, Abhijit Kulkarni1, Shyam Thakkar1.   

Abstract

OBJECTIVES: Acute and/or chronic pancreatitis has been implicated as an important risk factor for pancreatic cancer; however, the incidence and temporal relationship of pancreatitis before pancreatic cancer diagnosis are unclear. We aim to understand the role and incidence of pancreatitis temporally with the development of pancreatic cancer.
METHODS: A population-based study was used to investigate a temporal relationship between pancreatitis and pancreatic cancer diagnoses. Intervals of 3, 6, 12, 24, and 36 months were developed. Demographical data including age, sex, and race were also recorded and analyzed.
RESULTS: A total of 50,080 patients were found to have a diagnosis of pancreatic cancer, of which 7420 (14.8%) had prior diagnoses of pancreatitis. Of those, 92% were between the ages of 40 and 89 years. African Americans had a higher rate of pancreatitis before cancer diagnosis when compared with whites (21.2% vs 14.8%, P < 0.0001). Further analysis revealed that pancreatitis occurred in 81.3% of patients 3 months before a diagnosis of pancreas cancer and 98.9% had established diagnoses of pancreatic cancer within 3 years.
CONCLUSIONS: Screening of patients older than 40 years who have pancreatitis and unclear etiology of pancreatitis may be warranted, especially in African Americans and male individuals.

Entities:  

Mesh:

Year:  2019        PMID: 31404017     DOI: 10.1097/MPA.0000000000001367

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.

Authors:  Jian Zhu; Jian Lv; Jing Chen; Xuesong Zhang; Yong Ji
Journal:  Cell Cycle       Date:  2020-10-16       Impact factor: 5.173

Review 2.  Post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition as harbingers of pancreatic cancer.

Authors:  Maxim S Petrov
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

3.  Inflammatory-miR-301a circuitry drives mTOR and Stat3-dependent PSC activation in chronic pancreatitis and PanIN.

Authors:  Fugui Li; Miaomiao Wang; Xun Li; Yihao Long; Kaizhao Chen; Xinjie Wang; Mingtian Zhong; Weimin Cheng; Xuemei Tian; Ping Wang; Mingfang Ji; Xiaodong Ma
Journal:  Mol Ther Nucleic Acids       Date:  2022-01-19       Impact factor: 8.886

4.  Preoperative Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio and Lymphocyte-Monocyte Ratio in Peripheral Blood of Patients with Gastrointestinal Malignant Lesions.

Authors:  M O Petrescu; D Rădulescu; D Marinescu; V Șurlin; S Bordu; G S Petrescu
Journal:  Curr Health Sci J       Date:  2019-09-30

5.  Exploring and validating the clinical risk factors for pancreatic cancer in chronic pancreatitis patients using electronic medical records datasets: three cohorts comprising 2,960 patients.

Authors:  Xin Zhao; Ren Lang; Zhigang Zhang; Weiling Zhao; Zhiwei Ji; Hua Tan; Xiaobo Zhou
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

6.  Prenatal diethylstilbestrol exposure and risk of diabetes, gallbladder disease, and pancreatic disorders and malignancies.

Authors:  Rebecca Troisi; Marianne Hyer; Linda Titus; Julie R Palmer; Elizabeth E Hatch; Dezheng Huo; Kjersti M Aagaard; William C Strohsnitter; Robert N Hoover
Journal:  J Dev Orig Health Dis       Date:  2020-10-28       Impact factor: 3.034

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.